Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|5|738-743

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.5, 2014-03, pp. : 738-743

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor‐risk metastatic renal cell carcinoma

By  

CANCER, Vol. 121, Iss. 19, 2015-10 ,pp. : 3435-3443

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase 2 trial of the cyclin‐dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein‐expressing germ cell tumors

By  

CANCER, Vol. 121, Iss. 9, 2015-05 ,pp. : 1463-1468

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma

By Barker L. C.   Brand I. R.   Crawford S. M.  

Current Medical Research and Opinion, Vol. 25, Iss. 5, 2009-05 ,pp. : 1105-1109

Informa Healthcare

Access to resources Recommend Favorite

Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor–positive, human epidermal growth factor receptor 2–negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609)

By  

CANCER, Vol. 122, Iss. 19, 2016-10 ,pp. : 3032-3040

John Wiley & Sons Inc

Access to resources Recommend Favorite

Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial

By  

HEPATOLOGY, Vol. 67, Iss. 2, 2018-02 ,pp. : 514-523

John Wiley & Sons Inc

Access to resources Recommend Favorite